After the development of new drugs in China has gone through the stage of following imitation and imitation innovation, with the introduction of a series of policies to encourage the creation of new drugs, improve drug quality and promote industrial upgrading, China began to gradually move closer to the direction of original research and innovation in the real sense and move towards "global new".
Small molecule innovative drugs are still the main force of drug development. With the social development of aging population, the burden of chronic non communicable diseases represented by malignant tumors has increased, and a large number of unmet clinical needs have emerged, driving the development of China's small molecule innovative drug industry into the fast lane. In 2021, the global market scale of small molecule innovative drugs was about 180 billion US dollars, and the Chinese market scale was about 40 billion US dollars, accounting for more than 20% of the global market.
The development of small molecule innovative drugs has entered the era of targeting. According to the clear molecular biological mechanism, drugs are screened and developed for the gene mutations carried by the disease population. According to the target type and action mechanism, there are many types of small molecule innovative drugs on the market, such as kinase inhibitors, epigenetic inhibitors and proteasome inhibitors. With the development of Bt + IT technology, artificial intelligence and computer-aided drug development have gradually become the mainstream. Protac technology, allosteric regulators, deuterated drugs and other technical ideas are also highly expected.
Many excellent enterprises have emerged in China's small molecule innovative drug industry, including old brand large-scale generic pharmaceutical enterprises that have transformed to R & D innovative drugs, innovative pharmaceutical enterprises that have achieved leapfrog development based on early technology accumulation, industrial upgrading or business model innovation, and a large number based on their different product types and technical routes, The clinical start-up pharmaceutical enterprises participating in the differentiated competition jointly build the industry ecology of small molecule innovative drugs in China.
The development environment of China's small molecule innovative medicine industry is improving, and new products are emerging. However, there are still many challenges, such as insufficient innovation, insufficient R & D investment, limited product market space, rough capital operation and so on. In the future, the development of the industry will be further guided by clinical demand, driven by source innovation, dominated by China's big cycle and driven by China's foreign double cycle, look at the global market, benchmark and create new drugs, and promote the prosperity of the industry.
